In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 records · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Mixture Cerebrolysin | ||
|---|---|---|---|
| Identity | |||
| Kind | Small molecule | Mixture | |
| Area | Brain and mood | Brain and mood | |
| Evidence | |||
| Amount of evidence | 284 | 1,781 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 97 (6 in people) | 109 (96 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | None registered | 41 · 9 active2 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
No FDA approval and no central EU authorisation (EMA).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Bromantane | Cerebrolysin |
|---|---|---|
| Cognition and memoryNervous system and cognition | 211 | 26517293 |
| Exercise and physical function |
PepBank is a research reference. Talk to a doctor before you use any peptide.
No FDA approval and no central EU authorisation (EMA).
27423 |
14610343 |
| Adverse eventsWhole body | 27621 | 959041 |
|---|
| Receptor activity and mechanismNervous system and cognition | 7094912 | 2232312377 |
|---|
| Overall treatment effectNervous system and cognition | 33 | 3535 |
|---|
| Immune responseImmune and inflammation | 55 | 3724310 |
|---|
| Anxiety and moodNervous system and cognition | 19613 | 261313 |
|---|
| MortalityWhole body | 11 | 30228 |
|---|
| Inflammation markersImmune and inflammation | 55 | 508366 |
|---|
| Locomotor and behavioral activityNervous system and cognition | 2222 | 927 |
|---|
| Cell viability and deathImmune and inflammation | 1313 | 66 |
|---|
| Heart functionCardiovascular | 1010 | 66 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Bromantane | Cerebrolysin |
|---|---|---|
| Adverse eventsWhole bodyCompared as: share of people in the arm that got the peptide, in % | No comparable result 1 randomized-trial result measure it in another way or another unit. | 85% Treatment completion proportion · Cerebrolysin (G1) Saline (G2): 90% Dose studied: 20 mln = 402016 |
| Overall treatment effectNervous system and cognitionCompared as: value in the arm that got the peptide, in score | No randomized trial result 3 results from other study designs. | 2.84 score CIBIC+ Placebo: 3.68 score Dose studied: 20 mLn = 2422011 |
| Cognition and memoryNervous system and cognitionCompared as: difference from placebo, in p value | No randomized trial result 2 results from other study designs. | 0.02 p value ADAS-Cog comparison p value Dose studied: 30 mL once a day from Monday to Friday4 weeksn = 532000 |
| Exercise and physical functionNervous system and cognitionCompared as: value in the arm that got the peptide, in points | No randomized trial result 27 results from other study designs. | 2.3 points ALSFRS-R change Placebo decrease: 0.9 points Dose studied: 10 mL once daily, five days a week for the first month and three days a week for the next two months1 monthn = 202023 |
| Inflammation markersNervous system and cognitionCompared as: value in the arm that got the peptide, in lesions | No randomized trial result 5 results from other study designs. | 14 lesions Gadolinium-positive lesion count Dose studied: 20 mln = 42016 |
| MortalityWhole bodyCompared as: value in the arm that got the peptide, in % | No randomized trial result 1 result from other study designs. | 4.3% Deaths Placebo: 8.7% Dose studied: 30 mL daily10 daysn = 462014 |
No comparable result
1 randomized-trial result measure it in another way or another unit.
85%
Treatment completion proportion · Cerebrolysin (G1)
Saline (G2): 90%
Dose studied: 20 mln = 402016
No randomized trial result
3 results from other study designs.
2.84 score
CIBIC+
Placebo: 3.68 score
Dose studied: 20 mLn = 2422011
No randomized trial result
2 results from other study designs.
0.02 p value
ADAS-Cog comparison p value
Dose studied: 30 mL once a day from Monday to Friday4 weeksn = 532000
No randomized trial result
27 results from other study designs.
2.3 points
ALSFRS-R change
Placebo decrease: 0.9 points
Dose studied: 10 mL once daily, five days a week for the first month and three days a week for the next two months1 monthn = 202023
No randomized trial result
5 results from other study designs.
14 lesions
Gadolinium-positive lesion count
Dose studied: 20 mln = 42016
No randomized trial result
1 result from other study designs.
4.3%
Deaths
Placebo: 8.7%
Dose studied: 30 mL daily10 daysn = 462014
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
No registered trial that tests Bromantane found in ClinicalTrials.gov.
Top 3 of 41 trials, ranked by phase, then posted results and enrollment: 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
Ever Neuro Pharma GmbH242 participantsOct 2006 to Aug 2007
Vascular Dementia
Ever Neuro Pharma GmbH1,071 participantsSept 2006 to Feb 2011
Ischemic Stroke
Poznan University of Medical Sciences350 participants10 Jan 2023 to est. 31 Mar 2025
Acute Ischemic Stroke
2 more mention it but do not test it. They only measure it or name it in their text.